Abstract Library

#4343 Ga68-DOTATATE imaging on a state-of-the-art total-body PET/CT scanner with reducing administered activity

Introduction: Long-field of view PET/CT scanners allows total body scanning resulting higher sensitivity than traditional PET/CT scanners offering possible lower dose and faster scans.

Conference:

Presenting Author: Santillan N

Authors: Navalkissoor S, Santillan N, Chowdhury A, Ferreira B, Toumpanakis C,

Keywords: SSR, Ga68 DOTATATE, Neuroendocrine tumour, Quadra,

#3920 Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report primary

Introduction: The introduction of peptide receptor radionuclide therapy (PRRT) to the Philippines has allowed for novel approaches in the management of neuroendocrine tumors (NETs).

Conference:

Presenting Author: Chianpian C

Authors: Chianpian C, Bautista-Peñalosa P, Santos C, Bandong I,

Keywords: peptide receptor radionuclide therapy, metastatic pancreatic neuroendocrine tumor, Ga-68 DOTATATE, Lu-177 DOTATATE, Philippines,

#3825 Ga-68 DOTA-TOC PET/CT uptake by the parathyroid glands in patients with multiple endocrine neoplasia type 1 (MEN1)

Introduction: Primary hyperparathyroidism (PHPT) is the most common manifestation of MEN1. While Ga-68 DOTA-TOC PET/CT (GaPET) is increasingly used in this cohort for assessment of neuroendocrine tumors (NETs), there are limited data on its utility in assessing parathyroid disease.

Conference:

Presenting Author: Storan D

Authors: Storan D, Flynn S, O'Toole D, Almeamar H, O'Shea D,

Keywords: MEN1, PET CT, Gallium, Parathyroid,

#3726 Inflammation based index and tumor heterogeneity on pretherapeutic 68Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with 177Lu-oxodotreotide

Introduction: Peptide receptor radionuclide therapy with 177Lu oxodotreotide (LuPRRT) is a standard treatment for the management of patients with inoperable metastatic well-differentiated neuroendocrine tumors of the midgut (iNET). As LuPRRT becomes widely used for a heterogeneous population of NET patients, practical predictive biomarkers are needed. Inflammation based index (IBI) derived from serum C reactive protein and albumin is associated with progression free survival (PFS) and overall survival (OS) in patients with PRRT for NETs. Ga-68 DOTATOC PET/CT (DOTAPET) assessment of lesion heterogeneity was predictive for response to PRRT.

Conference:

Presenting Author: Vija L

Authors: Vija L, Dierickx L, Kanoun S, Texier J, Terroir M,

Keywords: LuPRRT, GaDOTA PET/CT, neuroendocrine tumor, outcome,

#3708 A strange biodistribution of 68Ga-DOTATOC PET/CT in a NET patient – Do you have some advice?

Introduction: We report the case of an abnormal distribution of Ga-68-DOTATOC PET/CT in a NET patient.

Conference:

Presenting Author: Grana C

Authors: Grana C, Gilardi L, Travaini L, Fracassi S, Muraglia L,

Keywords: Ga-68-DOTATOC PET/CT, GEP-NET, abnormal biodistribution, case report,